Search

Your search keyword '"Kuittinen, Taru"' showing total 166 results
Start Over Author "Kuittinen, Taru"
166 results on '"Kuittinen, Taru"'

1. Loss of CD34+ Cells and Effect of the Number of Viable Cryopreserved CD34+ Cells in the Infused Blood Grafts on Hematologic Recovery, Progression-Free Survival and Overall Survival in NHL Patients After Autologous Stem Cell Transplantation

Author

Partanen, Anu, Turunen, Antti, Valtola, Jaakko, Pyörälä, Marja, Kuittinen, Outi, Kuitunen, Hanne, Vasala, Kaija, Penttilä, Karri, Kuittinen, Taru, Mäntymaa, Pentti, Pelkonen, Jukka, Jantunen, Esa, and Varmavuo, Ville

Published
2023
Full Text
View/download PDF

2. Loss of CD34+ Cells and Effect of the Number of Viable Cryopreserved CD34+ Cells in the Infused Blood Grafts on Hematologic Recovery, Progression-Free Survival and Overall Survival in NHL Patients After Autologous Stem Cell Transplantation

Author

Partanen, Anu, Turunen, Antti, Valtola, Jaakko, Pyörälä, Marja, Kuittinen, Outi, Kuitunen, Hanne, Vasala, Kaija, Penttilä, Karri, Kuittinen, Taru, Mäntymaa, Pentti, Pelkonen, Jukka, Jantunen, Esa, and Varmavuo, Ville

Published
2023
Full Text
View/download PDF

3. Impact of the number of cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study

Author

Partanen, Anu, primary, Turunen, Antti, additional, Silvennoinen, Raija, additional, Valtola, Jaakko, additional, Pyörälä, Marja, additional, Siitonen, Timo, additional, Sikiö, Anu, additional, Putkonen, Mervi, additional, Sankelo, Marja, additional, Penttilä, Karri, additional, Kuittinen, Taru, additional, Mäntymaa, Pentti, additional, Pelkonen, Jukka, additional, Jantunen, Esa, additional, and Varmavuo, Ville, additional

Published
2022
Full Text
View/download PDF

4. Comparison of <scp>CD34</scp> + cell mobilization, blood graft cellular composition, and post‐transplant outcome in myeloma patients mobilized with filgrastim or pegfilgrastim added to low‐dose cyclophosphamide: A prospective multicenter study

Author

Kuittinen Taru, Mäntymaa Pentti, Siitonen Timo, Penttilä Karri, Pelkonen Jukka, Putkonen Mervi, Valtola Jaakko, Varmavuo Ville, Turunen Antti, Silvennoinen Raija, Sankelo Marja, Pyörälä Marja, Partanen Anu, Jantunen Esa, and Sikiö Anu

Subjects
medicine.medical_specialty, Cyclophosphamide, biology, Bortezomib, business.industry, Immunology, Urology, Hematology, Filgrastim, medicine.disease, CD19, 03 medical and health sciences, 0302 clinical medicine, Apheresis, 030220 oncology & carcinogenesis, PEG ratio, medicine, biology.protein, Immunology and Allergy, business, Pegfilgrastim, Multiple myeloma, 030215 immunology, medicine.drug
Abstract

Background Scarce data exist on the impact of granulocyte-colony stimulating factor (G-CSF) type on the mobilizing capacity of CD34+ cells, graft cellular composition, and outcome in myeloma (MM) patients. Patients and methods In this prospective multicenter study, 70 patients with MM received filgrastim (FIL) and 20 patients received pegfilgrastim (PEG) as a G-CSF after low-dose cyclophosphamide. Flow cytometry was used to analyze the mobilization of CD34+ cells and cellular composition of blood grafts, hematologic recovery, and survival after auto-SCT according to the G-CSF choice. Results The CD34+ cell yield of the first apheresis was higher in the FIL group (5.3 vs. 4.2 × 106 /kg, p = .025). The better mobilizing capacity was observed in the FIL group especially after bortezomib-based induction based on the higher first apheresis yield of CD34+ cells (7.5 vs. 4.4 × 106 /kg, p = .001). The median CD19+ cell count (1.0 vs. 0.4 × 106 /kg, p = .010) and the number of CD3+ T lymphocytes (43.1 vs. 31.8 × 106 /kg, p = .122) in the infused graft were higher in the patients mobilized with FIL. Both early (day +15) (56 vs. 108 × 109 /L, p = .002) and later platelet recovery at 6 months (191 vs. 226 × 109 /L, p = .026) were faster in the PEG group. Conclusion G-CSF type seems to impact on the mobilization capacity and cellular composition of infused graft and also platelet recovery post-transplant. A randomized study might be warranted to verify the effects of G-CSF choice in the mobilization field.

Published
2021

5. Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group

Author

Kolonen, Aarne, Sinisalo, Marjatta, Huhtala, Heini, Rimpiläinen, Johanna, Rintala, Hannele, Sankelo, Marja, Koivunen, Elli, Silvennoinen, Raija, Räty, Riikka, Ruutu, Tapani, Volin, Liisa, Porkka, Kimmo, Jantunen, Esa, Nousiainen, Tapio, Kuittinen, Taru, Penttilä, Karri, Pyörälä, Marja, Säily, Marjaana, Koistinen, Pirjo, Kauppila, Marjut, Itälä-Remes, Maija, Ollikainen, Hanna, Rauhala, Auvo, Kairisto, Veli, Pelliniemi, Tarja Terttu, Elonen, Erkki, Tampere University, Department of Internal medicine, Clinical Medicine, Health Sciences, and Department of Clinical Chemistry

Subjects
Leukemia, Myeloid, Acute, Neoplasm, Residual, Antineoplastic Combined Chemotherapy Protocols, Remission Induction, Cytarabine, Humans, Prospective Studies, Middle Aged, 3121 Internal medicine, Idarubicin, Thioguanine, Finland
Abstract

Objectives: AML-2003 study sought to compare the long-term efficacy and safety of IAT and IdAraC-Ida in induction chemotherapy of acute myeloid leukemia (AML) and introduce the results of an integrated genetic and clinical risk classification guided treatment strategy. Methods: Patients were randomized to receive either IAT or IdAraC-Ida as the first induction treatment. Intensified postremission strategies were employed based on measurable residual disease (MRD) and risk classification. Structured questionnaire forms were used to gather data prospectively. Results: A total of 356 AML patients with a median age of 53 years participated in the study. Long-term overall survival (OS) and relapse-free survival (RFS) were both 49% at 10 years. The median follow-up was 114 months. No significant difference in remission rate, OS or RFS was observed between the two induction treatments. Risk classification according to the protocol, MRD after the first and the last consolidation treatment affected the OS and RFS significantly (p

Published
2022

6. Impact of the number of cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study.

Author

Partanen, Anu, Turunen, Antti, Silvennoinen, Raija, Valtola, Jaakko, Pyörälä, Marja, Siitonen, Timo, Sikiö, Anu, Putkonen, Mervi, Sankelo, Marja, Penttilä, Karri, Kuittinen, Taru, Mäntymaa, Pentti, Pelkonen, Jukka, Jantunen, Esa, and Varmavuo, Ville

Subjects
STEM cell transplantation, OVERALL survival, CRYOPRESERVATION of cells, PROGRESSION-free survival, BLOOD cells
Abstract

Background: Prospective data on the impact of CD34+ cell loss during cryopreservation and the amount of cryopreserved CD34+ cells infused after high‐dose therapy on hematologic recovery and post‐transplant outcome in multiple myeloma (MM) are scarce. Patients and methods: This post‐hoc study aimed to investigate factors associating with CD34+ cell loss during cryopreservation and the effects of the infusion of a very low number (<1.0 × 106/kg, group A), low number (1–1.9 × 106/kg, group B), and optimal number (≥2 × 106/kg, group C) of thawed viable CD34+ cells on hematologic recovery, progression free survival, and overall survival after autologous stem cell transplantation among 127 patients with MM. Results: In group C, pegfilgrastim use (P = 0.001), plerixafor use (P = 0.039), and older age ≥ 60 years (P = 0.026) were associated with less loss of CD34+ cells during cryopreservation. Better mobilization efficacy correlated with greater CD34+ cell loss in group B (P = 0.013 and P = 0.001) and in group C (P < 0.001 and P < 0.001). Early platelet engraftment was slowest in group A (20 d vs 12 d in group B vs 11 d in group C, P = 0.003). The infused viable CD34+ cell count <1.0 × 106/kg seemed not to have influence on PFS (P = 0.322) or OS (P = 0.378) in MM patients. Conclusions: Cryopreservation impacts significantly on the CD34+ cell loss. A very low number of graft viable CD34+ cells did not affect PFS or OS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. Blood Graft and Outcome After Autologous Stem Cell Transplantation in Patients With Primary Central Nervous System Lymphoma

Author

Partanen, Anu, primary, Kuittinen, Outi, additional, Turunen, Antti, additional, Valtola, Jaakko, additional, Pyorala, Marja, additional, Kuitunen, Hanne, additional, Vasala, Kaija, additional, Kuittinen, Taru, additional, Mantymaa, Pentti, additional, Pelkonen, Jukka, additional, Jantunen, Esa, additional, and Varmavuo, Ville, additional

Published
2021
Full Text
View/download PDF

9. Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study

Author

Turunen, Antti, primary, Silvennoinen, Raija, additional, Partanen, Anu, additional, Valtola, Jaakko, additional, Siitonen, Timo, additional, Putkonen, Mervi, additional, Sankelo, Marja, additional, Pyörälä, Marja, additional, Kuittinen, Taru, additional, Penttilä, Karri, additional, Sikiö, Anu, additional, Savolainen, Eeva‐Riitta, additional, Mäntymaa, Pentti, additional, Pelkonen, Jukka, additional, Varmavuo, Ville, additional, and Jantunen, Esa, additional

Published
2021
Full Text
View/download PDF

13. Pleriksafori kantasolujen mobilisaatiossa autologista siirtoa varten

Author

Jantunen, Esa, Valtola, Jaakko, Partanen, Anu, Turunen, Antti, Kuittinen, Taru, Silvennoinen, Raija, Pyörälä, Marja, Mäntymaa, Pentti, Pelkonen, Jukka, Varmavuo, Ville, HUS Pää- ja kaulakeskus, Syöpätautien osasto, Hematologian yksikkö, HYKS erva, and Kymsote - Kymenlaakson sosiaali- ja terveyspalvelujen kuntayhtymä

Subjects
Lymphoma, 3122 Syöpätaudit, Heterocyclic Compounds, +therapy, Autografts, Multiple Myeloma, Prognosis, Transplantation, Autologous, Hematopoietic Stem Cell Mobilization, Stem Cell Transplantation
Abstract

Vertaisarvioitu. English summary Autologisella kantasolusiirrolla tuetulla intensiivihoidolla on keskeinen rooli etenkin multippelia myeloomaa sekä tietyissä tilanteissa lymfoomaa sairastavien potilaiden hoidossa. Huono tai epäonnistunut kantasolujen mobilisaatio ja keräys on tärkeä autologisen kantasolusiirron saatavuutta rajoittava tekijä. Noin vuosikymmenen ajan käytössä olleella pleriksaforilla voidaan usein auttaa potilaita, joiden kantasolut mobilisoituvat huonosti vaikuttamatta siirronjälkeiseen ennusteeseen. Pleriksaforin käytön on todettu vaikuttavan kerättyjen kantasolusiirteiden solukoostumukseen sekä potilaiden siirronjälkeiseen hematologiseen ja immunologiseen toipumiseen. Näiden löydösten kliininen merkitys vaatii vielä lisäselvityksiä, kuten optimaalisen autologisen kantasolusiirteen koostumuskin. Pleriksaforin optimaalisen ja etenkin kustannustehokkaan käytön kannalta on keskeistä tunnistaa oikeat potilasryhmät esimerkiksi tutkimuksissa varmennetuin algoritmein.

Published
2020

14. Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study

Author

Partanen, Anu, primary, Turunen, Antti, additional, Valtola, Jaakko, additional, Pyörälä, Marja, additional, Vasala, Kaija, additional, Kuittinen, Outi, additional, Kuitunen, Hanne, additional, Penttilä, Karri, additional, Keskinen, Leena, additional, Kuittinen, Taru, additional, Mäntymaa, Pentti, additional, Pelkonen, Jukka, additional, Varmavuo, Ville, additional, and Jantunen, Esa, additional

Published
2020
Full Text
View/download PDF

20. Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia

Author

Koskela, Hanna L.M., Eldfors, Samuli, Ellonen, Pekka, van Adrichem, Arjan J., Kuusanmäki, Heikki, Andersson, Emma I., Lagström, Sonja, Clemente, Michael J., Olson, Thomas, Jalkanen, Sari E., Majumder, Muntasir Mamun, Almusa, Henrikki, Edgren, Henrik, Lepistö, Maija, Mattila, Pirkko, Guinta, Kathryn, Koistinen, Pirjo, Kuittinen, Taru, Penttinen, Kati, Parsons, Alun, Knowles, Jonathan, Saarela, Janna, Wennerberg, Krister, Kallioniemi, Olli, Porkka, Kimmo, Loughran, Thomas P., Jr., Heckman, Caroline A., Maciejewski, Jaroslaw P., and Mustjoki, Satu

Published
2012
Full Text
View/download PDF

22. Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34+ cells is associated with improved survival

Author

Partanen, Anu, primary, Turunen, Antti, additional, Valtola, Jaakko, additional, Pyörälä, Marja, additional, Vasala, Kaija, additional, Kuittinen, Outi, additional, Kuitunen, Hanne, additional, Penttilä, Karri, additional, Kuittinen, Taru, additional, Mäntymaa, Pentti, additional, Pelkonen, Jukka, additional, Varmavuo, Ville, additional, and Jantunen, Esa, additional

Published
2020
Full Text
View/download PDF

23. Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study

Author

Turunen, Antti, primary, Valtola, Jaakko, additional, Partanen, Anu, additional, Ropponen, Antti, additional, Kuittinen, Outi, additional, Kuitunen, Hanne, additional, Vasala, Kaija, additional, Ågren, Lasse, additional, Penttilä, Karri, additional, Keskinen, Leena, additional, Savolainen, Eeva-Riitta, additional, Pyörälä, Marja, additional, Kuittinen, Taru, additional, Selander, Tuomas, additional, Mäntymaa, Pentti, additional, Pelkonen, Jukka, additional, Jantunen, Esa, additional, and Varmavuo, Ville, additional

Published
2020
Full Text
View/download PDF

24. CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non‐Hodgkinʼs lymphoma patients: results of the prospective multicenter GOA study

Author

Turunen, Antti, primary, Partanen, Anu, additional, Valtola, Jaakko, additional, Ropponen, Antti, additional, Siitonen, Timo, additional, Kuittinen, Outi, additional, Kuitunen, Hanne, additional, Putkonen, Mervi, additional, Sankelo, Marja, additional, Keskinen, Leena, additional, Savolainen, Eeva‐Riitta, additional, Pyörälä, Marja, additional, Kuittinen, Taru, additional, Silvennoinen, Raija, additional, Penttilä, Karri, additional, Sikiö, Anu, additional, Vasala, Kaija, additional, Mäntymaa, Pentti, additional, Pelkonen, Jukka, additional, Varmavuo, Ville, additional, and Jantunen, Esa, additional

Published
2020
Full Text
View/download PDF

25. A prospective comparison of pegfilgrastim and lipegfilgrastim combined with chemotherapy in the mobilization of CD34 + cells in NHL patients

Author

Partanen, Anu, primary, Turunen, Antti, additional, Valtola, Jaakko, additional, Vasala, Kaija, additional, Ågren, Lasse, additional, Penttilä, Karri, additional, Pyörälä, Marja, additional, Kuittinen, Taru, additional, Mäntymaa, Pentti, additional, Pelkonen, Jukka, additional, Jantunen, Esa, additional, and Varmavuo, Ville, additional

Published
2020
Full Text
View/download PDF

29. Mobilization characteristics, blood graft composition, and outcome in diffuse large B‐cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study.

Author

Partanen, Anu, Turunen, Antti, Valtola, Jaakko, Pyörälä, Marja, Vasala, Kaija, Kuittinen, Outi, Kuitunen, Hanne, Penttilä, Karri, Keskinen, Leena, Kuittinen, Taru, Mäntymaa, Pentti, Pelkonen, Jukka, Varmavuo, Ville, and Jantunen, Esa

Subjects
STEM cell transplantation, DIFFUSE large B-cell lymphomas, BLOOD cell count, LYMPHOMAS, PROGRESSION-free survival, BLOOD
Abstract

Background: Diffuse large B‐cell lymphoma (DLBCL) is a common indication for autologous stem cell transplantation (auto‐SCT). Study Design and Methods: This prospective noninterventional study aimed to evaluate the impact of mobilization characteristics and graft cellular content on hematologic recovery and outcome after auto‐SCT among 68 patients with DLBCL. Results: Better mobilization capacity as manifested by blood CD34+ cell count >32 × 106/L and CD34+ cell yield of the first apheresis >2.75 × 106/kg correlated with faster neutrophil (P =.005 and P =.017) and platelet (P =.002 and P <.001) recovery. A higher number of infused CD34+ cells (> 2.65 × 106/kg) was associated with better 5‐year overall survival (OS; 95% vs 67%, P =.012). The graft CD34+CD133+CD38− cell count >0.07 × 106/kg was predictive of better 5‐year OS (87% vs 63%; P =.008) and higher graft CD3+ cell count (>23.1 × 106/kg) correlated also with better 5‐year OS (80% vs 40%, P =.008). In multivariate analysis only disease status of CR I at auto‐SCT was associated with better progression‐free survival (P =.014) and OS (P =.039). Conclusion: The mobilization capacity of CD34+ cells impacted on early hematologic recovery in patients with DLBCL after auto‐SCT. Higher graft CD34+ cell count and both CD34+CD133+CD38− and CD3+ cells were also associated with better OS. The effect of optimal graft cellular composition on outcome in DLBCL should be evaluated in a randomized study. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

30. A prospective comparison of pegfilgrastim and lipegfilgrastim combined with chemotherapy in the mobilization of CD34+ cells in NHL patients.

Author

Partanen, Anu, Turunen, Antti, Valtola, Jaakko, Vasala, Kaija, Ågren, Lasse, Penttilä, Karri, Pyörälä, Marja, Kuittinen, Taru, Mäntymaa, Pentti, Pelkonen, Jukka, Jantunen, Esa, and Varmavuo, Ville

Subjects
GRANULOCYTE-colony stimulating factor, STEM cell transplantation, BLOOD cells, CANCER chemotherapy
Abstract

Background: Autologous stem cell transplantation (auto‐SCT) is a treatment approach in non‐Hodgkin lymphoma (NHL) patients. The options for mobilization of CD34+ cells to support high‐dose therapy are granulocyte‐colony stimulating factors (G‐CSFs) alone or after chemotherapy. Limited data exist on the efficacy of lipegfilgrastim (LIPEG) in the mobilization field. Patients and Methods: The present prospective nonrandomized study compared LIPEG 6 mg (n = 40) with pegfilgrastim (PEG) 6 mg (n = 37) in the mobilization of blood CD34+ cells after chemotherapy in NHL patients with comparable mobilizing chemotherapy and disease status before auto‐SCT. Results: Significantly higher blood CD34+ cell (B‐CD34+) counts were observed in the LIPEG group at the start of the first apheresis (44 vs 23 × 106/L, P =.009), in line with a higher collection yield of the first apheresis (3.3 vs 2.1 × 106/kg, P =.086) and total yield of CD34+ cells (4.7 vs 2.9 × 106/kg, P =.004). LIPEG proved to be a more effective G‐CSF, resulting in a higher B‐CD34+ cell peak (60 vs 32 × 106/L, P =.030) and higher proportion of excellent mobilizers (33% vs 8%, P =.008). The superiority of LIPEG was confirmed in the multivarite analysis concerning the CD34+ cell yield of the first apheresis day (P =.010) and the total yield (P =.001). Conclusion: The mobilization of blood grafts with LIPEG added to chemotherapy was associated with higher CD34+ cell apheresis yields than with PEG. A randomized study is warranted to verify these findings. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

31. A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy

Author

Petri, Sipola, Sipola, Petri, Esko, Vanninen, Vanninen, Esko, Esa, Jantunen, Jantunen, Esa, Tapio, Nousiainen, Nousiainen, Tapio, Mikko, Kiviniemi, Kiviniemi, Mikko, Juha, Hartikainen, Hartikainen, Juha, Taru, Kuittinen, and Kuittinen, Taru

Subjects
Adult, Male, Cardiac function curve, Heart Diseases, Anthracycline, Radionuclide ventriculography, CHOP, Ventricular Function, Left, Cardiac magnetic resonance imaging, medicine, Humans, Radiology, Nuclear Medicine and imaging, Doxorubicin, Prospective Studies, Radionuclide Ventriculography, Aged, Antibiotics, Antineoplastic, Ejection fraction, medicine.diagnostic_test, business.industry, Lymphoma, Non-Hodgkin, Reproducibility of Results, Stroke Volume, General Medicine, Middle Aged, medicine.disease, Treatment Outcome, Heart failure, cardiovascular system, Female, Nuclear medicine, business, Magnetic Resonance Angiography, Follow-Up Studies, medicine.drug
Abstract

PURPOSE To compare cardiac MRI and radionuclide ventriculography (RVG) in cardiac monitoring during anthracycline (doxorubicin)-based chemotherapy. MATERIALS AND METHODS We studied 10 previously untreated adult non-Hodgkin lymphoma patients. Left ventricular ejection fraction (LVEF) was assessed by MRI and RVG simultaneously. In addition, left ventricular (LV) and left atrial size were determined by MRI. Both MRI and RVG measurements were determined at baseline and then repeated after eight cycles of CHOP chemotherapy (cumulative doxorubicin dose of 400 mg/m²). Power calculations were made on the basis of reproducibility measurements. RESULTS Clinical heart failure was not observed in any patient during the study. MRI detected a statistically significant increase in LV end-diastolic volume (128 ± 39 vs. 151 ± 46 ml, P

Published
2012

32. Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34+ cells is associated with improved survival.

Author

Partanen, Anu, Turunen, Antti, Valtola, Jaakko, Pyörälä, Marja, Vasala, Kaija, Kuittinen, Outi, Kuitunen, Hanne, Penttilä, Karri, Kuittinen, Taru, Mäntymaa, Pentti, Pelkonen, Jukka, Varmavuo, Ville, and Jantunen, Esa

Subjects
LEUKAPHERESIS, STEM cell transplantation, T-cell lymphoma, BLOOD cells, GRANULOCYTE-colony stimulating factor
Abstract

The disease status at the time point of auto-SCT was CR1 in the majority of the patients (17 patients; 68%) and only one patient had experienced a relapse before auto-SCT. In addition, one patient with an apheresis yield of 1.8 × 10 SP 6 sp /kg CD34 SP + sp cells and another with a yield of 1.9 × 10 SP 6 sp /kg CD34 SP + sp cells were accepted to proceed to auto-SCT. Overall survival of the 25 patients with peripheral T-cell lymphoma according to yield of CD34+ cells of the first apheresis. [Extracted from the article]

Published
2020
Full Text
View/download PDF

33. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison

Author

Valtola, Jaakko, primary, Silvennoinen, Raija, additional, Ropponen, Antti, additional, Siitonen, Timo, additional, Säily, Marjaana, additional, Sankelo, Marja, additional, Terävä, Venla, additional, Putkonen, Mervi, additional, Kuittinen, Taru, additional, Pelkonen, Jukka, additional, Mäntymaa, Pentti, additional, Remes, Kari, additional, Varmavuo, Ville, additional, and Jantunen, Esa, additional

Published
2016
Full Text
View/download PDF

34. A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma

Author

Silvennoinen, Raija, primary, Anttila, Pekka, additional, Säily, Marjaana, additional, Lundan, Tuija, additional, Heiskanen, Jouni, additional, Siitonen, Timo, additional, Kakko, Sakari, additional, Putkonen, Mervi, additional, Ollikainen, Hanna, additional, Terävä, Venla, additional, Partanen, Anu, additional, Launonen, Kirsi, additional, Räsänen, Anu, additional, Sikiö, Anu, additional, Suominen, Merja, additional, Bazia, Piotr, additional, Kananen, Kristiina, additional, Selander, Tuomas, additional, Kuittinen, Taru, additional, Porkka, Kimmo, additional, Remes, Kari, additional, and Jantunen, Esa, additional

Published
2015
Full Text
View/download PDF

35. Stem Cell Graft Cellular Composition, Hematological and Immune Recovery in NHL Patients Mobilized with or without Plerixafor: A Prospective Comparison

Author

Valtola, Jaakko, primary, Varmavuo, Ville, additional, Ropponen, Antti, additional, Pyörälä, Marja, additional, Nihtinen, Anne, additional, Kutila, Anu, additional, Vasala, Kaija, additional, Lehtonen, Päivi, additional, Penttilä, Karri, additional, Kuittinen, Taru, additional, Nousiainen, Tapio, additional, Pelkonen, Jukka, additional, Mäntymaa, Pekka, additional, and Jantunen, Esa, additional

Published
2014
Full Text
View/download PDF

36. A Randomized Comparison of Low-Dose Cyclophosphamide + G-CSF Versus G-CSF Alone Mobilization after Lenalidomide-Bortezomib-Dexamethasone (RVD) Induction in Multiple Myeloma

Author

Silvennoinen, Raija, primary, Lundan, Tuija, additional, Anttila, Pekka, additional, Heiskanen, Jouni, additional, Säily, Marjaana, additional, Siitonen, Timo, additional, Kakko, Sakari, additional, Ollikainen, Hanna, additional, Vanhatalo, Seppo, additional, Putkonen, Mervi, additional, Terävä, Venla, additional, Kutila, Anu, additional, Partio, Mari, additional, Launonen, Kirsi, additional, Räsänen, Anu, additional, Sikiö, Anu, additional, Suominen, Merja, additional, Bazia, Piotr, additional, Kananen, Kristiina, additional, Kuittinen, Taru, additional, Porkka, Kimmo, additional, Remes, Kari, additional, and Jantunen, Esa, additional

Published
2014
Full Text
View/download PDF

38. Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients

Author

Varmavuo, Ville, primary, Rimpiläinen, Johanna, additional, Kuitunen, Hanne, additional, Nihtinen, Anne, additional, Vasala, Kaija, additional, Mikkola, Maija, additional, Kutila, Anu, additional, Lehtonen, Päivi, additional, Kuittinen, Taru, additional, Mäntymaa, Pentti, additional, Nousiainen, Tapio, additional, Kuittinen, Outi, additional, and Jantunen, Esa, additional

Published
2013
Full Text
View/download PDF

39. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

Author

Silvennoinen, Raija, primary, Kairisto, Veli, additional, Pelliniemi, Tarja‐Terttu, additional, Putkonen, Mervi, additional, Anttila, Pekka, additional, Säily, Marjaana, additional, Sikiö, Anu, additional, Opas, Jorma, additional, Penttilä, Karri, additional, Kuittinen, Taru, additional, Honkanen, Tuomo, additional, Lundán, Tuija, additional, Juvonen, Vesa, additional, Luukkaala, Tiina, additional, and Remes, Kari, additional

Published
2012
Full Text
View/download PDF

40. Comparison of Post-Transplant Outcomes in Non-Hodgkin Lymphoma (NHL) Patients Mobilized with or without Plerixafor Added to Chemomobilization

Author

Varmavuo, Ville, primary, Rimpiläinen, Johanna, additional, Nihtinen, Anne, additional, Vasala, Kaija, additional, Mikkola, Maija, additional, Lehtonen, Päivi, additional, Kuittinen, Taru, additional, Mäntymaa, Pentti, additional, Nousiainen, Tapio, additional, Kuittinen, Outi, additional, and Jantunen, Esa, additional

Published
2012
Full Text
View/download PDF

43. SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia

Author

Koskela, Hanna L.M., primary, Eldfors, Samuli, additional, Ellonen, Pekka, additional, van Adrichem, Arjan J., additional, Kuusanmäki, Heikki, additional, Andersson, Emma I., additional, Lagström, Sonja, additional, Clemente, Michael J., additional, Olson, Thomas, additional, Jalkanen, Sari E., additional, Majumder, Muntasir Mamun, additional, Almusa, Henrikki, additional, Edgren, Henrik, additional, Lepistö, Maija, additional, Mattila, Pirkko, additional, Guinta, Kathryn, additional, Koistinen, Pirjo, additional, Kuittinen, Taru, additional, Penttinen, Kati, additional, Parsons, Alun, additional, Knowles, Jonathan, additional, Saarela, Janna, additional, Wennerberg, Krister, additional, Kallioniemi, Olli, additional, Porkka, Kimmo, additional, Loughran, Thomas P., additional, Heckman, Caroline A., additional, Maciejewski, Jaroslaw P., additional, and Mustjoki, Satu, additional

Published
2012
Full Text
View/download PDF

45. Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications

Author

Koskela, Hanna, primary, Eldfors, Samuli, additional, Almusa, Henrikki, additional, Andersson, Emma, additional, Ellonen, Pekka, additional, Edgren, Henrik, additional, Koistinen, Pirjo, additional, Kuittinen, Taru, additional, Penttinen, Kati, additional, Knowles, Jonathan, additional, Saarela, Janna, additional, Kallioniemi, Olli, additional, Wennerberg, Krister, additional, Porkka, Kimmo, additional, Heckman, Caroline, additional, and Mustjoki, Satu, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results